Source: Annual Congress 2007 - Cystic fibrosis lung disease: what do we measure? What do we know?



Rating:

Share or cite this content

Citations should be made in the following way:
A. Pukhalsky, G. Shmarina, D. Pukhalskaya, L. Perederko, N. Kashirskaya, N. Kapranov (Moscow, Russian Federation). Can different approaches to anti-inflammatory therapy result in different outcomes in cystic fibrosis patients?. Eur Respir J 2007; 30: Suppl. 51, 345

Member's Comments

No comment yet.

Related content which might interest you: Whether low frequency of hepatobiliary abnormalities in cystic fibrosis patients is associated with anti-inflammatory treatment? Source: Annual Congress 2008 - Cystic fibrosis: a disease with many aspects Year: 2008 Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Long-term outcomes of antifibrotic treatments in patients with idiopathic pulmonary fibrosis: Real-world experience Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Antithrombotics in idiopathic pulmonary fibrosis patients with concomitant antifibrotic therapy: a single centre real world experience Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Do different combinations of bronchodilator therapies have different effects on health status in patients with COPD? Source: Eur Respir J 2003; 22: Suppl. 45, 52s Year: 2003 Results of antifibrotic drugs in the treatment of idiopathic pulmonary fibrosis. A real life study. Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Efficacy of switching antifibrotic therapy in idiopathic pulmonary fibrosis: real life data Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Do causes influence clinical, functional and quality of life aspects on patients with bronchiectasis not associated with cystic fibrosis? Source: International Congress 2019 – Chronic cough, a1-antitrypsin deficiency and other conditions Year: 2019 The role of inhaled antibiotics in bronchial infection Source: Eur Respir Monogr 2013; 60: 120-126 Year: 2013 Are invasive physiological measures necessary for an optimal setting of pressure support in young patients with cystic fibrosis? Source: Annual Congress 2003 - Physiology of NIV: understanding the effects and chosing the best settings Year: 2003 Health-economic aspects of cystic fibrosis screening and therapy Source: Eur Respir Monogr 2014; 64: 304-319 Year: 2014 Do patients with cystic fibrosis participating in clinical trials demonstrate placebo response ? A meta-analysis. Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis Year: 2019 What influences patient choice of antifibrotic treatment in IPF? Source: Virtual Congress 2020 – Challenges and updates in nursing care around the world Year: 2020 Trying to find a cure for cystic fibrosis: CFTR biomarkers as outcomes Source: Eur Respir J 2013; 42: 1156-1157 Year: 2013 Trying to find a cure for cystic fibrosis: CFTR biomarkers as outcomes Source: Eur Respir J 2013; 42: 1155 Year: 2013 Clinical efficacy data for new diagnostic tool for the selection of the most effective antibiotics for patients with cystic fibrosis Source: Virtual Congress 2020 – Microbiology and antimicrobial strategies in cystic fibrosis Year: 2020 Personalised anti-inflammatory therapy for bronchiectasis and cystic fibrosis: selecting patients for controlled trials of neutrophil elastase inhibition Source: ERJ Open Res, 5 (1) 00252-2018; 10.1183/23120541.00252-2018 Year: 2019 Long-term outcomes and clinical worsening in cystic fibrosis patients with at least one residual function mutation Source: International Congress 2018 – Cystic fibrosis in adults: current research Year: 2018 Clinical response to elexacaftor/tezacaftor/ivacaftor for cystic fibrosis patients in a compassionate use setting Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis Year: 2020